Repros Therapeutics

Read more
CEO Avatar

President & CEO

Larry Dillaha

CEO Approval Rating

75/100

Founded:

1987

Status:

PrivateSubsidiary of Allergan Plc

Est. Annual Revenue
$ < 1M
Agree?
Est. Employees
24
Agree?

REPROS THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Repros Therapeutics's company profile
CEO Avatar

Larry Dillaha

President & CEO

75/100
24
$0
$ < 1M
View Profile
1
Repros Therapeutics's Competitor - Evofem logo
Saundra Pelletier's photo - CEO of Evofem

Saundra Pelletier

CEO

100/100
30
$249.3M
$3.4M
View Profile
2
Repros Therapeutics's Competitor - PregLem S.A. logo
Ksenija Pavletic Aranicki's photo - CEO of PregLem S.A.

Ksenija Pavletic Aranicki

CEO

84/100
40
$59.9M
$15.7M
View Profile
3
Repros Therapeutics's Competitor - OvaScience logo
CEO Avatar

CEO

- -
37
$140.4M
$ < 1M
View Profile
4
Repros Therapeutics's Competitor - Lipocine logo
Mahesh V. Patel's photo - Chairman & CEO of Lipocine

Mahesh V. Patel

Chairman & CEO

90/100
10
$76.2M
$ < 1M
View Profile
5
Repros Therapeutics's Competitor - ObsEva logo
Brian O’Callaghan's photo - CEO of ObsEva

Brian O’Callaghan

CEO

85/100
45
$326.3M
$ < 1M
View Profile
6
Repros Therapeutics's Competitor - Progyny logo
David Schlanger's photo - CEO of Progyny

David Schlanger

CEO

82/100
210
$213.1M
$450M
View Profile
7
Repros Therapeutics's Competitor - TherapeuticsMD logo
Robert G. Finizio's photo - Co-Founder & CEO of TherapeuticsMD

Robert G. Finizio

Co-Founder & CEO

90/100
241
$322.5M
$84.8M
View Profile
8
Repros Therapeutics's Competitor - ASCEND Therapeutics logo
Nicholas Hart's photo - President & CEO of ASCEND Therapeutics

Nicholas Hart

President & CEO

82/100
900
- -
$14M
View Profile
9
Repros Therapeutics's Competitor - Celmatix logo
Piraye Yurttas Beim's photo - Founder & CEO of Celmatix

Piraye Yurttas Beim

Founder & CEO

70/100
76
$20.4M
$22M
View Profile
10
Repros Therapeutics's Competitor - Agile Therapeutics logo
Alfred Altomari's photo - Chairman & CEO of Agile Therapeutics

Alfred Altomari

Chairman & CEO

90/100
13
$192.5M
$4.7M
View Profile
11
Repros Therapeutics's Competitor - Forendo Pharma logo
Risto Lammintausta's photo - Co-Founder & CEO of Forendo Pharma

Risto Lammintausta

Co-Founder & CEO

89/100
21
$33.8M
$2.4M
View Profile
12
Repros Therapeutics's Competitor - Colorado Center for Reproductive Medicine logo
Jon Pardew's photo - President & CEO of Colorado Center for Reproductive Medicine

Jon Pardew

President & CEO

68/100
30
- -
$10M
View Profile

Missing a competitor? Contribute!

Evofem is one of Repros Therapeutics's top competitors. Evofem was founded in 2009, and its headquarters is in San Diego, California. Like Repros Therapeutics, Evofem also works within the Biotechnology sector. Evofem has 123 more employees than Repros Therapeutics.

PregLem S.A. is Repros Therapeutics's #2 rival. PregLem S.A. was founded in 2006 in Geneva, Geneva. PregLem S.A. operates in the Biotechnology industry. PregLem S.A. generates $15.4M more revenue than Repros Therapeutics.

OvaScience is a top competitor of Repros Therapeutics. OvaScience is a Private company that was founded in Waltham, Massachusetts in 2011. OvaScience is in the Biotechnology field. OvaScience has 13 more employees vs. Repros Therapeutics.

Repros Therapeutics Acquisitions

No recent acquisitions found related to Repros Therapeutics

Repros Therapeutics Funding History

No recent funding data found related to Repros Therapeutics

Repros Therapeutics Investments

No recent investments found related to Repros Therapeutics

Repros Therapeutics News

April 18, 2018BioPortfolio

Repros Therapeutics Inc RPRX Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14032018 Prices from USD $250

SummaryRepros Therapeutics Inc Repros formerly Zonagen Inc is a biopharmaceutical company that develo... See more »
January 27, 2018Reuters

BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene

* REPROS ANNOUNCES NEGATIVE OPINION FROM THE EMA FOR ENCLOMIPHENE... See more »
December 18, 20174-traders

Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX

(4-traders.com) NEW YORK, Dec. 18, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner... See more »
December 16, 2017DirectorsTalk Interviews

Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency

THE WOODLANDS, Texas, Dec. 15, 2017 - Repros Therapeutics Inc. (NASDAQ:RPRX) ("Repros" or the "Compan... See more »
December 12, 2017Reuters

BRIEF-Repros Therapeutics Announces Acquisition By Allergan

* REPROS THERAPEUTICS INC.® ANNOUNCES ACQUISITION BY ALLERGAN PLC... See more »
November 29, 2017BioPortfolio

Repros Therapeutics Inc RPRX Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14112017 Prices from USD $250

SummaryRepros Therapeutics Inc Repros formerly Zonagen Inc is a biopharmaceutical company that develo... See more »
November 13, 2017Reuters

BRIEF-Repros Therapeutics Q3 loss per share $0.04

* Repros Therapeutics Inc.® reports third quarter 2017 financial results... See more »

Repros Therapeutics Press Releases

August 31, 2016Business Wire

Global Uterine Leiomyoma (Uterine Fibroids) Pipeline Report 2016 - Review of 10 Companies/Institutions & Drug Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Uterine Leiomyoma (U... See more »
May 5, 2016Business Wire

Repros Therapeutics, Abbott Labs, Bayer - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Male Hypogonadism Gl... See more »
April 14, 2016MarketersMedia

4 Small Cap Stocks That Have To Be On Your Watchlist Today

NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that... See more »

Social Media

Repros Therapeutics Headquarters

2408 Timberloch Pl B-7

The Woodlands, Texas77380

281-719-3400

Driving Directions »

Trending Companies

Repros Therapeutics Summary

ABOUT

Overview

Repros Therapeutics develops oral small molecule drugs for the treatment of hormonal and reproductive system disorders. Repros Therapeutics was founded in 1987. Repros Therapeutics' headquarters is located in The Woodlands, Texas, USA 77380. Repros T...

CEO

Repros Therapeutics's President & CEO, Larry Dillaha, currently has an approval rating of 75%. Repros Therapeutics's primary competitors are Evofem, PregLem S.A. & OvaScience.

Frequently Asked Questions about Repros Therapeutics

  1. When was Repros Therapeutics founded?

    Repros Therapeutics was founded in 1987
  2. Who is Repros Therapeutics's CEO?

    Repros Therapeutics's CEO is Larry Dillaha
  3. How much revenue does Repros Therapeutics generate?

    Repros Therapeutics generates $ < 1M in revenue
  4. How much funding does Repros Therapeutics have?

    Repros Therapeutics has historically raised $0 in funding
  1. Where is Repros Therapeutics's headquarters?

    Repros Therapeutics's headquarters is in The Woodlands Texas, USA
  2. How many employees does Repros Therapeutics have?

    Repros Therapeutics has 24 employees
  3. What sector does Repros Therapeutics operate in?

    Repros Therapeutics is in Biotechnology
  4. Who are Repros Therapeutics's competitors?

    Repros Therapeutics's top competitors are Evofem, PregLem S.A., OvaScience